Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma
NCT07283224 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2026-05-12
Summary
This is a retrospective, observational, single-center study conducted at the Hematology Unit of the IRCCS Azienda Ospedaliero-Universitaria di Bologna. The study aims to integrate genomic, clinical, and imaging data-all previously collected and pseudonymized-from earlier spontaneous studies carried out by the Hematology Unit. The main goal is to explore how genetic, clinical, and imaging features relate to disease outcomes and to develop predictive models using artificial intelligence (AI) and machine learning (ML). These models may help forecast disease progression and treatment response in the future. By combining different types of data, the research team hopes to develop new methods to predict disease progression and treatment outcomes. No new procedures, tests, or patient visits are required for this study. All the information analyzed will come from existing data collected as part of past clinical practice or previous research projects. Once anonymized, it will no longer be possible to identify individual patients. The anonymized dataset will be securely developed and stored by the bioinformatics team at the Hematology Unit of IRCCS AOUBO.
Conditions
- Myeloma Multiple
Sponsors & Collaborators
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-06-30
- Primary Completion
- 2027-01-01
- Completion
- 2028-01-01
Countries
- Italy
Study Locations
More Related Trials
-
Institut Paoli Calmettes Multiple Myeloma Database
NCT02869555 ·Status: RECRUITING
-
Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients
NCT03409692 ·Status: COMPLETED
-
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
NCT03127761 ·Status: RECRUITING
-
Multiple Myeloma Minimal Residual Disease
NCT02627261 ·Status: COMPLETED
-
A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain
NCT02946333 ·Status: COMPLETED
-
Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients
NCT00551928 ·Status: COMPLETED ·Phase: PHASE3
-
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
NCT02322320 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06577025 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
European Myeloma Network (EMN) Sample Project
NCT06237803 ·Status: RECRUITING
-
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT04722146 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Autologous Transplantation for Multiple Myeloma
NCT00378222 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
NCT01734928 ·Status: COMPLETED ·Phase: PHASE3
-
Immunophenotyping of Plasma Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From Multiple Myeloma (MM) Patients
NCT05428163 ·Status: COMPLETED
-
Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies
NCT02997813 ·Status: COMPLETED
-
Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma
NCT00327314 ·Status: UNKNOWN ·Phase: PHASE2
-
Bone Pain in Multiple Myeloma- a Translational Study
NCT04273425 ·Status: UNKNOWN
-
Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia
NCT00832234 ·Status: COMPLETED ·Phase: PHASE2
-
Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients
NCT00358020 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
NCT02726581 ·Status: COMPLETED ·Phase: PHASE3
-
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
NCT00075829 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain
NCT03602755 ·Status: COMPLETED
-
Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
NCT01554852 ·Status: UNKNOWN ·Phase: PHASE3
-
Treatment Optimization in Patients With Untreated Multiple Myeloma
NCT02145598 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders.
NCT04819607 ·Status: UNKNOWN
-
Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
NCT01782963 ·Status: COMPLETED ·Phase: PHASE2